ArticleJournal of addiction medicine
Development and Validation of an Image-Based Deep Learning Tool for Identification of Xylazine-Associated Wounds.
Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesAccurate identification of xylazine-associated wounds (XAWs) is critical to providing timely and optimal management; however, discerning the etiology of wounds by appearance alone poses a clinical challenge. This study sought to develop an accessible and accurate approach for XAW diagnosis using a deep learning tool applied to wound photographs.
methodsPublicly accessible wound photographs were curated from academic publications, Reddit, and news media to develop, train, and test the deep learning tool. XAWs were defined by provided clinical confirmation or self-reported descriptions associated with each image. The data set included images of 114 xylazine-associated and 1710 nonxylazine wounds from 17 distinct pathologies. Four deep learning models (DenseNet121, EfficientNetB0, ResNet34, and SENet154) were trained on 1185 images (65%) and 163 for validation (9%) to predict xylazine exposure and tested using 476 unseen wound images (26%).
resultsAll 4 deep learning models achieved consistent diagnostic performance on 476 unseen wound images (accuracy: 97.5%-98.5%; AUROC: 96.8%-99.7%; weighted F1 score: 97.2%-98.5%). High specificity, reaching 100.0%, was observed across the 4 models. Sensitivity ranged from 60.0% to 80.0% across the 4 models, with SENet154 demonstrating robust performance across all metrics. Qualitative assessment demonstrated accurate identification of XAWs with high-confidence exclusion of xylazine exposure in wounds attributed to trauma, surgery, pressure, or venous ulcers.
conclusionsThis novel deep learning tool can enable accurate identification of XAW. With further validation, this tool may offer an accessible and automated approach to guide wound care, augment bedside clinical medicine assessments, and equip public health efforts to monitor xylazine's geographic distribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.